BeOne Medicines
ONC
#780
Rank
HK$247.44 B
Marketcap
HK$2,385
Share price
-3.77%
Change (1 day)
36.00%
Change (1 year)
BeOne Medicines formerly known as BeiGene, is a multinational pharmaceutical company engaged in the R&D, commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

Earnings for BeOne Medicines (ONC)

Earnings in 2026 (TTM): HK$5.90 Billion

According to BeOne Medicines's latest financial reports the company's current earnings are HK$5.73 Billion. In 2025 the company made an earning of HK$3.85 Billion, an increase over its 2024 earnings that were of -HK$4.45 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for BeOne Medicines from 2015 to 2026

Annual earnings

Year Earnings Change
2026 (TTM) HK$5.90 B53.36%
2025 HK$3.85 B-186.57%
2024 -HK$4.45 Billion-52.95%
2023 -HK$9.46 Billion-32.52%
2022 -HK$14.02 Billion24.39%
2021 -HK$11.27 Billion-13.21%
2020 -HK$12.98 Billion72.69%
2019 -HK$7.52 Billion36.01%
2018 -HK$5.53 Billion616.83%
2017 -HK$0.78 Billion-15.24%
2016 -HK$0.91 Billion107.91%
2015 -HK$0.44 Billion

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
OPKO Health
OPK
-HK$1.25 Billion-121.09%๐Ÿ‡บ๐Ÿ‡ธ USA
Onconova Therapeutics
ONTX
-HK$0.15 Billion-102.40%๐Ÿ‡บ๐Ÿ‡ธ USA